One of the major obstacles to successful chemotherapy of cancer is multidrug resistance. Increased drug efflux out of tumour cells has generally been implied as the mechanism underlying drug resistance. Drug resitance has been associated with overproduction of the drug-efflux pump, called gp 170 or P-glycoprotein (Pgp). In turn, there has been overexpression of the associated gene (Chen et al., 1986; Roninson, 1991) . Various attempts to overcome multidrug resistance have been studied (Beck, 1991; Chen et al., 1991) . Most experimental and clinical efforts to circumvent multidrug resistance have used drugs such as verapamil, quinidine and cyclosporine in an attempt to block the efflux function of Pgp (Tsuruo et al., 1982; Twentyman et al., 1987; Hu et al., 1990) . Other investigators have attempted to use the monoclonal antibody against Pgp to modulate multidrug resistance phenotype (Tsuruo et al., 1989; FitzGerald et al., 1987; Beck, 1991; Pearson et al., 1991) . Some attempts have been made to develop new drugs or to chemically modify existing drugs in such a way as to decrease the energy-dependent drug efflux pump and thereby increase tumour cell killing (Watanabe et al., 1988; Sheldon et al., 1989; Coley et al., 1990; Ripamonti et al., 1992) .
In the present report we investigated the therapeutic efficacy of the conjugates of proteins and doxorubicin (DXR) on growth of DXR resistant cell line in vitro.
Materials and methods

Cell line
The azo dye-induced rat ascites hepatoma cell line, AH66 parental cell line, AH66P, and the daunorubicin-resistant mutant subline (AH66DR) were maintained in the RPMI 1640 media as described previously (Ohkawa et al., 1989a) . Both types of cells are minimally adherent to culture plates and can be detached by pipetting. The AH66DR represented a classic multidrug resistance line with cross-resistance to DXR.
Preparation of the conjugates ofproteins and DXR Binding of DXR to proteins were carried out using the method described by Hurwitz et al. (1975) . Briefly, 3 mg of bovine serum albumin (BSA) or goat immunoglobulin G (IgG) and 0.5 mg DXR (labelled with/without '4C) in 1 ml of phosphate buffered saline was cross linked using glutaraldehyde solution. Free and bound drugs were separated by gel filtration on Sephadex G-100 (Pharmacia, Uppsala, Sweden). The degree of substitution was estimated by the drug absorbance at 495 nm or by radioactivity. Protein concentration was measured by Bio-Rad protein assay kit (BioRad, Richmond, CA, USA). The conjugate of glutaraldehyde to BSA without DXR was also prepared. 
SDS-PAGE and Western blotting analysis
Cell extracts diluted in SDS-PAGE sample buffer were fractionated using SDS-PAGE (7.5% separating gel) followed by electrotransfer on the nitrocellulose paper as previously reported (Ohkawa et al., 1989b Figure 5 ).
Discussion o \\
Daunorubicin-resistant mutant cell line, AH66DR, has been previously reported (Ohkawa et al., 1989a) to show cross- (Thorgeirsson et al., 1987; Ueda et al., 1987; Huang et al., 1992; Miyamoto et al., 1992 (Theibaut et al., 1987) .
The addition of ammonium chloride to the medium moderately reduced the cytotoxic effect of the conjugate as well as the intracellular accumulation of the conjugate. This may be secondary to an inhibition of drug-uptake. It further suggests that the growth inhibitory effects of the conjugate involve the endocytosis of the conjugate and this may be critically dependent on the low pH of the post-endocytotic compartment. Our results clearly indicate that the pharmacokinetics of the chemically modified DXR are different in intracellular behaviour from that of free DXR, which is actively excreted from the cytoplasm by an energy-dependent pump mechanism (Chen et al., 1986; Roninson et al., 1991; Beck, 1991) . It has been reported that the conjugates were taken-up by endocytosis of the plasma membrane into the cytoplasm and metabolised in the lysosomes (Trouet et al., 1972; DeDuve et al., 1974; Shen & Ryser, 1979; Leserman et al., 1981; Heath et al., 1983; Stahl, 1983; Waldmann, 1991) . We assume that the in vitro effectiveness of the protein-DXR conjugate shown in AH66DR cells is via a similar mechanism.
The improved drug sensitivity of multidrug resistant cells to DXR conjugated with specific antibody against the cells or to DXR-loaded nanosphares has been recently reported (Sheldon et al., 1989; Cuvier et al., 1992 2-00 0 l ity of the resultant conjugates between IgG and BSA as a partner protein. For human use it would be possible to substitute human serum albumin for either BSA or goat IgG. To potentiate the cell killing activity of the conjugate it would be desirable to increase the molar ratio of the drug against the molar amount of protein. This could possibly be accomplished by using improved methods for conjugation of 20-50 molecules of the drugs with one molecule of protein.
Examples of this include the immunoconjugates of IgG antibody against alpha-fetoprotein with anticancer drugs (Tsukada et al., 1982; Kato et al., 1983; Tsukada et al., 1984; Ohkawa et al., 1986) . Further investigations in vitro are planned to elucidate the exact mechanism(s) via which conjugates are able to overcome the multidrug resistance.
